Blog Knowledge Base

Trial Designs: Non-inferiority vs. Superiority vs. Equivalence

Understand superiority, non-inferiority, and equivalence trials, how their hypotheses differ, and how trial design impacts…

CertaraFebruary 3, 2026

Live Events

Phoenix Roadshow 2026 – Florence

CertaraFebruary 2, 2026

Publication

Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants

This study, published in Clinical Pharmacology & Therapeutics (CPT), shows how population pharmacokinetic modeling supports…

CertaraFebruary 2, 2026

On-Demand Webinar

Modeling Population PK with Power, Speed, and Ease-of-Use (Phoenix® NLME & Pirana®)

Discover population PK modeling made faster and easier with Phoenix NLME and Pirana in this…

CertaraJanuary 30, 2026

On-Demand Webinar

Regulatory-Trusted Software for Smarter PK/PD Workflows (Phoenix WinNonlin®)

This on demand session demonstrates how Phoenix WinNonlin® and other tools work together within Phoenix®…

CertaraJanuary 27, 2026

Blog

How Model-Informed Drug Development (MIDD) Strengthens Drug Asset Valuation and Answers the Questions Investors Care About Most

Learn how Model-Informed Drug Development strengthens drug asset valuation by reducing uncertainty, predicting clinical performance,…

CertaraJanuary 26, 2026

Webinar

Milliliters, Milligrams, and Moles: Keeping Up with Units in NCA

Danielle PillsburyJanuary 22, 2026

Webinar

Non-compartmental analysis of statin pharmacokinetics in pharmacogenetics research

CertaraJanuary 22, 2026

Webinar

Subcutaneous absorption model

CertaraJanuary 22, 2026

Publication

Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients

This article explores how model-based meta-analysis (MBMA) performs when combining aggregate data and individual patient…

CertaraJanuary 22, 2026

Clinical Pharmacology

Trial Designs: Non-inferiority vs. Superiority vs. Equivalence

Phoenix Roadshow 2026 – Florence

Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants

Modeling Population PK with Power, Speed, and Ease-of-Use (Phoenix® NLME & Pirana®)

Regulatory-Trusted Software for Smarter PK/PD Workflows (Phoenix WinNonlin®)

How Model-Informed Drug Development (MIDD) Strengthens Drug Asset Valuation and Answers the Questions Investors Care About Most

Milliliters, Milligrams, and Moles: Keeping Up with Units in NCA

Non-compartmental analysis of statin pharmacokinetics in pharmacogenetics research

Subcutaneous absorption model

Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients

Newsletter sign up

Quick links

Solutions

Contact